Ponatinib

Results: 34



#Item
21HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use ICLUSIG safely and effectively. See full prescribing information for ICLUSIG. ICLUSIG® (ponatinib) tablets for oral

HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use ICLUSIG safely and effectively. See full prescribing information for ICLUSIG. ICLUSIG® (ponatinib) tablets for oral

Add to Reading List

Source URL: www.accessdata.fda.gov

Language: English - Date: 2013-12-23 15:37:55
22FDA Drug Safety Communication: FDA requires multiple new safety measures for leukemia drug Iclusig; company expected to resume marketing This information is in follow-up to the FDA Drug Safety Communication: FDA asks man

FDA Drug Safety Communication: FDA requires multiple new safety measures for leukemia drug Iclusig; company expected to resume marketing This information is in follow-up to the FDA Drug Safety Communication: FDA asks man

Add to Reading List

Source URL: www.fda.gov

Language: English
23Iclusig® (ponatinib) 15 mg and 45 mg tablets for oral use.

Iclusig® (ponatinib) 15 mg and 45 mg tablets for oral use.

Add to Reading List

Source URL: www.accessdata.fda.gov

Language: English - Date: 2013-12-20 09:46:57
24MEDICATION GUIDE Iclusig® (eye-CLUE-sig) (ponatinib)

MEDICATION GUIDE Iclusig® (eye-CLUE-sig) (ponatinib)

Add to Reading List

Source URL: www.accessdata.fda.gov

Language: English - Date: 2013-12-23 15:37:56
25REMS Document Initial Approval[removed]NDA[removed] Iclusig® (ponatinib) tablets

REMS Document Initial Approval[removed]NDA[removed] Iclusig® (ponatinib) tablets

Add to Reading List

Source URL: www.fda.gov

Language: English
26Establishment of a novel CML model using Multi Hit technology: CMLMULTIHIT Tatsuaki Mizutani, Japan International Incoming Fellowship Ludwig-Boltzmann Institute for Cancer Research, Austria

Establishment of a novel CML model using Multi Hit technology: CMLMULTIHIT Tatsuaki Mizutani, Japan International Incoming Fellowship Ludwig-Boltzmann Institute for Cancer Research, Austria

Add to Reading List

Source URL: ec.europa.eu

Language: English - Date: 2012-05-30 09:15:10
27OTT[removed]profile-of-bosutinib-and-its-clinical-potential-in-the-treat

OTT[removed]profile-of-bosutinib-and-its-clinical-potential-in-the-treat

Add to Reading List

Source URL: www.ncbi.nlm.nih.gov

Language: English
28Arzneimittelnebenwirkungen Ponatinib (Iclusig) Erhöhtes Risiko von Gefäßverschlüssen Ponatinib (Iclusig) ist erst seit August

Arzneimittelnebenwirkungen Ponatinib (Iclusig) Erhöhtes Risiko von Gefäßverschlüssen Ponatinib (Iclusig) ist erst seit August

Add to Reading List

Source URL: www.marseille-verlag.com

Language: German - Date: 2014-04-22 07:18:15
    29Gene Therapy and Molecular Biology Vol 16, page 10 Gene Ther Mol Biol Vol 16, 10-29, 2014 Survival assessment and Optimization of BCR/ABL-KD

    Gene Therapy and Molecular Biology Vol 16, page 10 Gene Ther Mol Biol Vol 16, 10-29, 2014 Survival assessment and Optimization of BCR/ABL-KD

    Add to Reading List

    Source URL: www.gtmb.org

    Language: English - Date: 2014-04-08 07:34:01
    30HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use ICLUSIG safely and effectively. See full prescribing information for ICLUSIG. ICLUSIG® (ponatinib) tablets for oral

    HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use ICLUSIG safely and effectively. See full prescribing information for ICLUSIG. ICLUSIG® (ponatinib) tablets for oral

    Add to Reading List

    Source URL: s368855769.onlinehome.us

    Language: English - Date: 2014-02-10 09:17:42